MarkWide Research - Global Market Intelligence Platform
Report Details
Historical Year
2020-2024
Base Year
2025
Forecast Period
2026-2036
Published Date
May 2026
No. of Pages
173 Pages
Delivery Format
PDF + Excel
Home›Industries›Healthcare›Specialty Medicine›Bacteriophages Therapy Market

Bacteriophages Therapy Market Size, Share, and Industry Trends Forecast 2026-2036

The Bacteriophages Therapy Market valued at $1.8 Billion in 2026 is projected to expand to $8.42 Billion by 2035, advancing at a 18.70% CAGR over the analysis window. Hospital procurement of phage-based treatments against multidrug-resistant infections is accelerating as clinicians face limited antibiotic alternatives. The FDA's expanded access program for investigational phage therapies is streamlining compassionate-use pathways for critically ill patients. Demand is concentrating in the United States, where specialized phage therapy centers and academic medical institutions are building clinical evidence and reimbursement frameworks.

Bacteriophages Therapy Market Analysis

The split between engineered phage platforms and natural phage preparations is shifting as developers pursue distinct regulatory and commercial pathways. Eliava Biopreparations anchors the natural phage segment through its historic Georgian phage library and established production infrastructure. BiomX differentiates by leveraging synthetic biology to engineer phages with enhanced host range and lytic activity against specific bacterial targets.

Bacteriophages therapy deploys viruses that infect and lyse bacteria to treat resistant infections, with engineered variants incorporating CRISPR-Cas systems or modified tail fibers to expand target specificity beyond wild-type constraints. Natural phages occupy the mature commercial tier in Eastern European markets, while engineered phages capture R&D investment and partnership value in North American and Western European pipelines. Topical application leads current clinical utilization for wound and skin infections, though intravascular delivery represents the fastest-growing modality as bloodstream infection trials advance.

The FDA, EMA, and national regulators such as Health Canada are developing adaptive frameworks for phage therapy approval, with the FDA's Phage Therapy Guidance and EMA's ATMP classification shaping development costs and timeline expectations for sponsors. The EU Green Deal's antimicrobial resistance action plan is directing public funding toward alternatives to conventional antibiotics, expanding reimbursement pilot programs for phage treatments in member states. Stakeholders must monitor evolving pharmacovigilance requirements for live biological products and position manufacturing capabilities to meet batch-to-batch consistency standards that diverge from small-molecule norms.

Bacteriophages Therapy Market Size and Forecast

Market Dynamics

The FDA's expanded access program for investigational phage therapies is compressing compassionate-use timelines and forcing developers to build manufacturing capacity ahead of traditional approval pathways.

Growth Catalysts

  • Antimicrobial resistance mandates:The EU Green Deal's antimicrobial resistance action plan is directing public funding toward alternatives to conventional antibiotics across member states.
  • Hospital procurement:Academic medical centers in the United States are establishing specialized phage therapy centers to address multidrug-resistant infections with limited antibiotic alternatives.
  • Engineered phage platforms:Synthetic biology approaches incorporating CRISPR-Cas systems are expanding target specificity beyond wild-type phage constraints.

Market Restraints

  • Batch-to-batch consistency requirements:Pharmacovigilance standards for live biological products diverge sharply from small-molecule manufacturing norms, elevating quality control costs.
  • Regulatory fragmentation:Divergent classification between the FDA's Phage Therapy Guidance and EMA's ATMP framework creates parallel development tracks with incompatible dossier requirements.
  • Natural phage supply concentration:Eastern European production infrastructure anchors commercial natural phage supply, creating geographic dependency for established therapies.

Strategic Opportunities

  • Intravascular delivery modalities:Bloodstream infection trials are advancing the fastest-growing administration route beyond topical wound applications.
  • Reimbursement pilot programs:EU member states are expanding coverage frameworks for phage treatments under public health antimicrobial resistance initiatives.
  • CRISPR-phage convergence:Integration of programmable nuclease systems with engineered phage backbones enables precision targeting of resistance gene reservoirs.

Industry Challenges

  • Phage-host range optimization:Tail fiber engineering requires specialized microbiology talent pools that remain concentrated in academic rather than commercial settings.
  • Adaptive trial design execution:Personalized phage matching protocols complicate traditional randomized controlled trial structures and statistical powering.

Report Scope

MarkWide Research
AttributesDetails
Report TitleBacteriophages Therapy Market
Market Size in 2026$1.8 Billion
Market Size in 2035$8.42 Billion
CAGR (2026 – 2036)18.7%
Historical Year2020-2024
Base Year2025
Forecast Period2026-2036
Segmentation
Product Type: Natural Phages, Engineered Phages, Phage Preparation Kits, Phage-Encoded Enzymes
Application: Infectious Diseases, Veterinary Medicine, Food Safety, Biomedical Research
End User: Hospitals, Research Laboratories, Pharmaceutical Companies, Agriculture Sector
Delivery Mode: Oral Administration, Topical Application, Intravascular Delivery, Intramuscular Injection
Companies CoveredEliava Biopreparations, BiomX, Armata Pharmaceuticals, Phagelux, Adaptive Phage Therapeutics, Intralytix, Locus Biosciences, TechnoPhage, Pherecydes Pharma, Others
Regions Covered
North America: US, Canada, Mexico
Europe: Germany, Italy, France, UK, Spain, Denmark, Sweden, Austria, Belgium, Finland, Turkey, Poland, Russia, Greece, Switzerland, Netherlands, Norway, Portugal, Rest of Europe
Asia Pacific: China, Japan, India, South Korea, Indonesia, Malaysia, Kazakhstan, Taiwan, Vietnam, Thailand, Philippines, Singapore, Australia, New Zealand, Rest of Asia Pacific
South America: Brazil, Argentina, Colombia, Chile, Peru, Rest of South America
Middle East & Africa: Saudi Arabia, UAE, Qatar, South Africa, Israel, Kuwait, Oman, North Africa, West Africa, Rest of MEA

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Bacteriophages Therapy Market Emerging Trajectories

Engineered phage platforms are displacing natural preparations in Western development pipelines while regulatory frameworks coalesce around live biological product standards.

CRISPR-Cas9 integration into phage genomes is automating bacterial defense evasion by programming site-specific DNA cleavage alongside lytic replication. Contract development organizations serving infectious disease sponsors are adopting these platforms at accelerating pace. The technology is automating precision targeting of resistance plasmids that previously required strain-specific natural phage isolation.

EMA's ATMP classification for genetically modified phage products is compressing development timelines for engineered candidates while elevating manufacturing facility requirements. Sponsors must now demonstrate replication-competent organism containment protocols that exceed traditional biologics standards. Western European pipelines are restructuring around this framework, with natural phage developers pursuing separate botanical drug pathways.

Hospital formulary committees are consolidating phage therapy procurement through centralized pharmacy and therapeutics committees rather than individual physician compassionate-use requests. Specialized infectious disease pharmacists are displacing ad hoc procurement in academic medical centers. The United States exhibits this concentration most visibly, where phage therapy centers negotiate master service agreements with production facilities.

Bacteriophages Therapy Market Segmentation

Bacteriophages Therapy Market Segment

Phage therapy segmentation reveals divergent commercial pathways between mature natural products and emerging engineered platforms. Each dimension carries distinct regulatory, manufacturing, and reimbursement implications that shape stakeholder investment priorities.

Product Type:

Natural phage preparations dominate current commercial volume while engineered variants command premium pricing and partnership valuations.

  • Natural Phages:Wild-type bacteriophage cocktails isolated from environmental sources target broad bacterial host ranges without genetic modification. Demand concentrates in Eastern European markets where Eliava Biopreparations and established phage libraries anchor supply, constrained by batch-to-batch variability that complicates Western regulatory dossiers.
  • Engineered Phages:Synthetic biology platforms incorporate CRISPR-Cas systems and modified tail fibers to expand host specificity and evade bacterial defense mechanisms. Investment from North American and Western European biotech sponsors is accelerating clinical pipelines, though EMA's ATMP classification elevates manufacturing facility requirements beyond traditional biologics standards.
  • Phage Preparation Kits:Standardized isolation and propagation systems for hospital-based phage matching protocols.
  • Phage-Encoded Enzymes:Purified lysins and depolymerases derived from phage genomes for enzymatic bacterial lysis without live virus administration.

Today's leader: Natural Phages. Tomorrow's challenger: Engineered Phages.

Application:

Clinical infectious disease treatment captures the majority of reimbursed utilization while veterinary and food safety applications expand through regulatory pilot programs.

  • Infectious Diseases:Human therapeutic applications target multidrug-resistant bacterial infections including Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Hospital procurement in the United States is accelerating through specialized phage therapy centers at academic medical institutions facing limited antibiotic alternatives.
  • Biomedical Research:Phage display technologies and bacterial genetics tools drive demand from pharmaceutical discovery programs. Research laboratories in Germany and the Netherlands are expanding phage library collections under EU Green Deal antimicrobial resistance funding mechanisms.
  • Veterinary Medicine:Livestock and companion animal applications targeting bacterial mastitis and wound infections.
  • Food Safety:Phage-based biocontrol agents for Listeria and Salmonella reduction in processing environments.

Infectious Diseases commands current revenue concentration. Biomedical Research exhibits the steepest expansion trajectory as tool applications multiply.

End User:

Hospital pharmacy committees are consolidating procurement authority previously dispersed across individual physician compassionate-use requests.

  • Hospitals:Specialized infectious disease pharmacists at academic medical centers now negotiate master service agreements with phage production facilities. The FDA's expanded access program is compressing compassionate-use timelines, forcing hospitals to build internal phage matching and administration protocols ahead of traditional approval pathways.
  • Pharmaceutical Companies:Partnership structures with engineered phage developers are restructuring Western European pipelines around EMA ATMP frameworks. Sponsors must demonstrate replication-competent organism containment protocols that exceed small-molecule manufacturing norms.
  • Research Laboratories:Academic and contract research organizations advancing phage biology and host-range optimization.
  • Agriculture Sector:Crop protection and livestock health applications through phage-based biocontrol products.

Hospitals anchor near-term demand. Pharmaceutical Companies are reshaping long-term commercial architecture through platform licensing.

Delivery Mode:

Topical administration leads current clinical utilization while intravascular protocols represent the highest-value expansion opportunity.

  • Topical Application:Direct phage administration to wound beds, burns, and skin infections offers straightforward pharmacokinetic profiles and localized bacterial lysis. Clinical evidence from Georgian and Polish treatment centers supports reimbursement negotiations in Western European pilot programs.
  • Intravascular Delivery:Intravenous and intra-arterial administration for bloodstream infections, endocarditis, and deep-seated systemic infections. Trials in the United States and Switzerland are advancing this modality fastest as clinicians confront carbapenem-resistant Enterobacteriaceae with no remaining antibiotic options.
  • Oral Administration:Gastrointestinal targeting of enteric pathogens including Clostridioides difficile and pathogenic E. coli.
  • Intramuscular Injection:Depot formulations for sustained phage release in soft tissue infections.

Topical Application holds current utilization leadership. Intravascular Delivery is gaining share fastest as systemic infection trials mature.

Bacteriophages Therapy Market Segmentation

Need this report tailored to your region?

Request specific countries, segments, or companies — tailored to your requirements.

Regional Outlook

Microbiology specialists concentrate in Tbilisi, Boston, and Basel, anchoring phage therapy development across three continents. These talent clusters shape regulatory filing strategies and manufacturing investment patterns. National health systems deploy distinct reimbursement mechanisms for live biological products.

United States

FDA's expanded access program compresses compassionate-use timelines for critically ill patients. Academic medical centers in San Diego and Pittsburgh build specialized phage therapy centers with master service agreements. Hospital procurement committees consolidate purchasing authority previously dispersed across individual physicians.

Georgia

Eliava Biopreparations maintains historic phage libraries dating to Soviet-era research programs. The national pharmaceutical regulator supports traditional botanical drug pathways for natural phage preparations. Tbilisi anchors commercial natural phage supply infrastructure serving Eastern European markets.

Switzerland

Swissmedic's adaptive frameworks attract engineered phage developers seeking streamlined ATMP classifications. Basel's infectious disease research cluster advances intravascular delivery trials for bloodstream infections. Cantonal hospital networks pilot reimbursement programs for multidrug-resistant infection treatments.

United Kingdom

NHS England's specialized commissioning frameworks accommodate phage therapy for patients with no remaining antibiotic options. London's Guy's and St Thomas' NHS Foundation Trust operates dedicated phage matching services. Oxford and Cambridge research corridors attract CRISPR-phage convergence startups.

France

ANSM coordinates with EMA on genetically modified organism containment standards for engineered phage facilities. Lyon and Paris academic hospitals participate in EU-funded antimicrobial resistance treatment networks. The country's national pharmaceutical regulator pilots batch-to-batch consistency protocols for live biological products.

Bacteriophages Therapy Market Vendor Landscape

Top-tier vendors anchor engineered phage platforms, while natural phage specialists occupy established commercial tiers. The market exhibits bifurcated structure with synthetic biology developers capturing Western partnership valuations and traditional producers maintaining Eastern European volume. Two strategic archetypes dominate: CRISPR-enhanced platform builders and historic phage library curators. Competitive moves center on manufacturing capacity expansion ahead of regulatory approvals and geographic licensing agreements to access hospital procurement channels.

Within the engineered platform tier, BiomX and Locus Biosciences represent synthetic biology approaches with modified host ranges. Eliava Biopreparations anchors the natural phage archetype through established production infrastructure. Adaptive Phage Therapeutics occupies a position between these vectors with personalized phage matching protocols.

Leading Market Players
Eliava Biopreparations
BiomX
Armata Pharmaceuticals
Phagelux
Adaptive Phage Therapeutics
Intralytix
Locus Biosciences
TechnoPhage
Pherecydes Pharma
Others
Please Note: The list provided is preliminary and subject to refinement. Our final study will profile 15–20 companies, and we are happy to customize the selection to align with your specific needs.

Supply Flow & Price Mechanics

Academic medical center procurement committees in the United States negotiate master service agreements that bundle phage matching protocols with administration services, compressing price transparency and elevating contract-based pricing over transactional spot purchases.

Pricing Analysis

Service bundling separates comprehensive phage therapy packages from unbundled phage product-only transactions. Three-tier pricing structure across personalized matching, standardized cocktails, and research-grade preparations reflects regulatory certification tiers and manufacturing facility standards. Cost compression in natural phage tiers is intensifying because Eastern European supply expansion outpaces Western regulatory qualification timelines. Hospital pharmacy committees exhibit lowest price sensitivity for intravascular delivery protocols targeting carbapenem-resistant infections with no antibiotic alternatives.

Supply Chain Analysis

Dual-sourcing requirements from hospital procurement committees mandate qualification of both natural phage libraries and engineered phage production facilities. Manufacturing concentrates in Georgia, Switzerland, and the United States, drawing from environmental phage isolation, synthetic biology platforms, and GMP bioreactor infrastructure. Supply chain risk centers on single-source vulnerability for strain-specific phage matching protocols that require months-long isolation cycles. Distribution runs through specialized infectious disease pharmacists at academic medical centers rather than traditional wholesale channels.

Bacteriophages Therapy Market SWOT Analysis

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Analyst Recommendations

This market functions as a geographic-arbitrage play where developers exploit cost differentials between Georgian natural phage production infrastructure and Western European ATMP facility investment requirements.

For Market Incumbents: To counter engineered phage platform displacement, natural phage specialists should pursue botanical drug pathway diversification in EU member states while building captive GMP capacity in Switzerland to access Swissmedic's streamlined frameworks. Eliava Biopreparations anchors defensive positioning through historic library depth that requires decades to replicate.

For New Entrants and Emerging Players: Contract development organizations represent the most accessible channel partner type for engineered phage sponsors seeking manufacturing scale without facility ownership. White-space concentration sits in intravascular delivery formulation services and CRISPR-phage convergence tooling for research laboratories. New entrants should target veterinary medicine applications in North America where regulatory pathways remain less fragmented than human therapeutic frameworks.

For Investors and Strategic Acquirers: Large pharmaceutical companies with infectious disease portfolio gaps are the most active acquirer in this space, seeking platform access over single-asset exposure. Long-term viability hinges on reimbursement pilot program maturation into permanent coverage mechanisms. The signal to watch is FDA guidance finalization on replication-competent organism containment standards that would clarify manufacturing investment thresholds.

Strategic InitiativeIndustry Significance
Manufacturing Scale-UpGMP facility investment in Switzerland accelerates Swissmedic ATMP qualification timelines for engineered phage sponsors.
Regulatory Approval PathwayFDA Phage Therapy Guidance finalization would compress compassionate-use-to-approval transition for U.S. developers.
Licensing AgreementGeorgian phage library access agreements enable Western sponsors to bypass years of environmental isolation work.
Clinical Trial AdvancementBloodstream infection trials in Basel and Pittsburgh advance intravascular delivery toward reimbursement eligibility.
Pipeline DiversificationPhage-encoded enzyme programs reduce live-virus regulatory burden while maintaining antibacterial mechanism.

Methodological Framework

Multiple input streams — primary interviews with infectious disease pharmacists, regulatory affairs specialists, and phage manufacturing executives, secondary validation through FDA expanded access records, EMA ATMP classification documents, ClinicalTrials.gov registries, and hospital procurement databases — were reconciled through bottom-up and top-down triangulation.

Data-stream reconciliation applied across the analysis window modeled segmentation dimensions including product type, application, end user, and delivery mode alongside regional regulatory cluster variations. CAGRs were derived from patient volume projections, reimbursement pilot expansion trajectories, and manufacturing capacity buildout schedules without assuming linear adoption curves.

Revisions become necessary when FDA guidance finalization delays, EMA ATMP facility inspection backlogs, or major antibiotic resistance outbreak containment success materialize. Deviation in hospital formulary committee consolidation timelines would shift the outlook materially.

Need Custom Data?

Can't find what you're looking for? Our analysts can build a custom report tailored to your exact requirements.

1,000+

Global Clients

150+

Countries Covered

65,000+

Reports Available

Frequently Asked Questions

Why Work With MWR

Trusted by 1,000+ businesses across 150+ countries for high-stakes market decisions.

Ready to access intelligence that moves business?

Browse Reports →

Trusted by Global Leaders

From Fortune-level organizations to global SMEs, we provide intelligence for high-stakes decisions.

Multi-Language Support

Research available in French, German, Spanish, Chinese, and more.

ISO & IAF Certified

Globally aligned quality standards ensuring methodological discipline and data integrity.

Competitive Relevance

Free inclusion of 3–4 additional companies of your choice in every report.

Customized Insights

Tailored intelligence for market entry, niche expansion, or competitive benchmarking.

Post-Sale Assistance

Dedicated coordination to help interpret findings and address queries post-delivery.

Cutting-Edge Methods

Structured data collection, advanced analytics, and expert validation for reliable forecasts.

Value for Investment

Credible, structured intelligence at a cost that makes strategic sense.

What Our Clients Say

"

My team needed the real numbers on AI spending for our Reinvention Services work. MarkWide delivered. No fluff, just a clear look at where the money is actually going. It saved us about three weeks of guesswork.

Accenture

"

We recently leaned on MarkWide Research for a deep dive into the evolving snacking habits within Southeast Asia. Their report on the premium biscuit segment was exceptionally detailed, providing us with the specific consumer sentiment data we needed to refine our regional flavor strategy. It wasn't just a data dump; the cultural nuances they captured helped us avoid several localization pitfalls.

Mondelez

Director of Global Consumer Insights

"

For a recent engagement in the automotive sector, we needed rigorous, independent verification of EV battery recycling capacities. MWR delivered a report that made our work easier. Their ability to segment the competitive landscape by chemical composition and regional throughput was exactly the kind of 'hard-to-find' intel that our team was looking for.

BCG

"

We were looking for a report on Xcelerator ecosystem's potential and got in touch with MarkWide's team through one of my old colleagues who worked with them in the past. Their research team was incredibly polite and were always available for us which was important for my team as this was a custom project. Their methodology for tracking industrial IoT adoption gave our R&D heads the clarity needed to prioritize our next-gen sensor development.

Siemens

Head of Industrial Digitalization

"

During a recent M&A project, we needed a fast, reliable breakdown of the Fintech landscape in Southeast Asia. MarkWide came through with a report that was actually readable and focused on the metrics that matter. It saved my team a good week of primary research, which, given our timelines, was a massive win.

KPMG

Advisory Partner

"

We tapped MarkWide Research for a deep dive into the ESG reporting software market. At Deloitte, our clients expect us to have the most current insights, and this report didn't disappoint. It provided a breakdown of the competitive field that was far more detailed than what we were expecting.

Deloitte

Lead Consultant, Sustainability Services

"

For our semiconductor division at Samsung, the supply chain forecast from MarkWide was incredibly useful. It provided a realistic outlook on raw material availability that helped us refine our production timelines. No fluff, just the data we needed to make a tough call.

Samsung

"

The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarkWide Research, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer. Their customer first approach and high value engagement model have given us great analysis and excellent value for money.

3M

"

I can share that it was a positive experience wherein MarkWide Research demonstrated flexibility to adapt to our needs and delivered an excellent report that fits all our requirements. Personally, I liked the timely follow up by the team and we will definitively reach out in case more research support is required.

VITO

Buy Now